医学
人口
死因
前列腺癌
癌症
流行病学
队列
内科学
疾病
队列研究
乳腺癌
绝对风险降低
标准化死亡率
肿瘤科
置信区间
环境卫生
作者
Tianwang Guan,Yanting Jiang,Zehao Luo,Yinglan Liang,Manting Feng,Zhenxing Lu,Min Yi,Yintong Teng,Ruoyun Zhou,Ling-Hua Zeng,Kaiyi Chi,Caiwen Ou,Minsheng Chen
出处
期刊:Age and Ageing
[Oxford University Press]
日期:2023-05-01
卷期号:52 (5)
被引量:6
标识
DOI:10.1093/ageing/afad068
摘要
Abstract Background previous studies have focused on the risk of cardiovascular disease (CVD)-related death in individual cancers, adolescents or all cancers. Objective to evaluate the risk of CVD-related death in older patients with cancer. Methods older patients with cancer (over 65 years) of 16 cancers diagnosed between 1975 and 2018 were screened out from the Surveillance, Epidemiology and End Results program. The proportion of deaths, competing risk regression models, standardized mortality ratios (SMRs) and absolute excess risks (AERs) were used to assess the risk of CVD-related death. Results this study included 1,141,675 older patients (median follow-up: 13.5 years). Of the 16 individual cancers, the risk of CVD death exceeded primary neoplasm death in older patients with cancers of the breast, endometrium, vulva, prostate gland, penis and melanoma of the skin over time (high competing risk group). Compared to the general older population, older patients with cancer had higher SMR and AER of CVD-related death (SMR: 1.58–4.23; AER: 21.16–365.89), heart disease-related death (SMR: 1.14–4.16; AER: 16.29–301.68) and cerebrovascular disease-related death (SMR: 1.11–4.66; AER: 3.02–72.43), with the SMR trend varying with CVD-related death competing risk classifications. The risk of CVD-related death in the high-competing risk group was higher than in the low-competing risk group. Conclusions for older patients with cancer, six of 16 individual cancers, including breast, endometrium, vulva, prostate gland, penis and melanoma of the skin was at high risk of CVD-related death. Management for long-term cardiovascular risk in older patients with cancer is needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI